Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S451000, C514S453000, C514S454000, C514S455000, C514S025000, C514S027000, C514S033000, C514S034000, C540S478000, C549S432000
Reexamination Certificate
active
07863321
ABSTRACT:
The present invention relates to synergistic combinations of the compound 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from anthracyclines and topisomerase II inhibitors, which have anti-tumor activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from etoposide, and doxorubicin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.
REFERENCES:
patent: 3678077 (1972-07-01), Nakanishi et al.
patent: 4602034 (1986-07-01), Briet et al.
patent: 4704355 (1987-11-01), Bernstein et al.
patent: 5126129 (1992-06-01), Wiltrout et al.
patent: 5281620 (1994-01-01), Denny et al.
patent: 5464826 (1995-11-01), Grindey et al.
patent: 5620875 (1997-04-01), Hoffman et al.
patent: 5817684 (1998-10-01), Fleisch et al.
patent: 5863904 (1999-01-01), Nabel et al.
patent: 5910505 (1999-06-01), Fleisch et al.
patent: 6174873 (2001-01-01), Wrenn
patent: 6194454 (2001-02-01), Dow
patent: 6667337 (2003-12-01), Wilson
patent: 6806257 (2004-10-01), Lee et al.
patent: 2001/0041713 (2001-11-01), Waldstreicher et al.
patent: 2003/0003092 (2003-01-01), Krissansen et al.
patent: 2004/0087611 (2004-05-01), Baguley et al.
patent: 2004/0204480 (2004-10-01), Wilson et al.
patent: 2005/0131059 (2005-06-01), Wang et al.
patent: 2006/0009505 (2006-01-01), Baguley et al.
patent: 2007/0060637 (2007-03-01), Wilson et al.
patent: 2007/0082937 (2007-04-01), Baguley et al.
patent: 2008/0070847 (2008-03-01), Wilson et al.
patent: 2008/0070848 (2008-03-01), Wilson et al.
patent: 2008/0070886 (2008-03-01), Wilson et al.
patent: 2015265 (1970-10-01), None
patent: 19721211 (1998-11-01), None
patent: 0278176 (1988-08-01), None
patent: 0326149 (1989-08-01), None
patent: 0385467 (1990-09-01), None
patent: 0488718 (1992-06-01), None
patent: 0551200 (1993-07-01), None
patent: 0743064 (1996-11-01), None
patent: 0584001 (1997-05-01), None
patent: 0121285.1 (2001-09-01), None
patent: 0206839.3 (2002-05-01), None
patent: 0225508.1 (2002-11-01), None
patent: 0604114.9 (2006-03-01), None
patent: 0157387.7 (2006-08-01), None
patent: 0517386.9 (2006-08-01), None
patent: 09040690 (1997-02-01), None
patent: 2001247459 (2001-09-01), None
patent: 336259 (1999-06-01), None
patent: 506060 (2000-07-01), None
patent: 99121332 (2001-07-01), None
patent: 2195946 (2003-01-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO 94/23753 (1994-10-01), None
patent: WO 95/09621 (1995-04-01), None
patent: WO 96/32418 (1996-10-01), None
patent: WO 96/36347 (1996-11-01), None
patent: WO 97/04761 (1997-02-01), None
patent: WO 97/34482 (1997-09-01), None
patent: WO 98/25600 (1998-06-01), None
patent: WO 98/25615 (1998-06-01), None
patent: WO 98/25616 (1998-06-01), None
patent: WO 98/42332 (1998-10-01), None
patent: WO 98/42334 (1998-10-01), None
patent: WO 98/42335 (1998-10-01), None
patent: WO 98/42336 (1998-10-01), None
patent: WO 98/42337 (1998-10-01), None
patent: WO 98/42345 (1998-10-01), None
patent: WO 98/42346 (1998-10-01), None
patent: WO 98/42650 (1998-10-01), None
patent: WO 00/10600 (2000-03-01), None
patent: WO 00/15176 (2000-03-01), None
patent: WO 00/16798 (2000-03-01), None
patent: WO 00/48591 (2000-08-01), None
patent: WO 00/76497 AI (2000-12-01), None
patent: WO 01/34135 (2001-05-01), None
patent: WO 01/34137 (2001-05-01), None
patent: WO 01/34197 (2001-05-01), None
patent: WO 01/34198 (2001-05-01), None
patent: WO 02/09700 (2002-02-01), None
patent: WO 03/020259 (2003-03-01), None
patent: WO 03/080044 (2003-10-01), None
patent: WO 2004/039363 (2004-05-01), None
patent: WO 2005/027974 (2005-03-01), None
patent: WO 2007/023302 (2007-03-01), None
patent: WO 2007/023307 (2007-03-01), None
patent: WO 2009/053681 (2009-04-01), None
Calabresi et al, Goodman and Gilman's , The pharmacological basis of therapeutics, 9th edition, 1995.
Cliffe et al., International Journal of Radiation Oncology Biology Physics, (1994) vol. 29, No. 2, pp. 373-377.
Zhou et al., British Journal of Clinical Pharmacology, (Aug. 2001), vol. 52, No. 2, pp. 129-136.
Siemann et al., Proceedings of the American Association for Cancer Research Annual Meeting, (Mar. 2000), No. 41, p. 525.
Goodman &Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, (1996), Calabresi et al., Section X, Chemotherapy of Neoplastic Diseases, pp. 1225-1229.
Pruijn et al. Mechanisms of enhancement of the antitumor activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol., 1997, col. 39, pp. 541-546.
Van Moorsel et al. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochemical Pharmacology, 1999, vol. 57, pp. 407-415.
Peters et al. Pharmacology & Therapeutics, 2000, vol. 87, pp. 227-253.
Hande, Biochemica et Biophysica Acta 1400 , 1998 173-184.
Siemann et al. abstract only, Proceedings of the American Association for Cancer Research, 2000, vol. 41, p. 525.
Antisoma. “AACR presentation highlights possible new cancer targets for Antisoma's DMXAA”; Press release of Antisoma plc.; Jul. 14, 2003.
Kelland, et al.; “Single Agent Activity and Potentiation of the Antitumor Activity of Paclitaxel and Gemcitabine with the Vascular Targeting Agent, 5,6-dimethylxanethenone-4-acetic acid (DMXAA) in Human Tumour Xenografts”; (poster) Jul. 13, 2003.
Gaolin, et al., “Developments in research on cancer therapy with tumor vascular endothelial cell”, Article Ref. No. 0258-879X; (2000) 10-0987-04; (English Translation of “Development of the Study on the Anti-cancer Treatment against Endothelial Cells of Blood Vessel of Tumors”, Zhang Li and Liu Gaolin,Academic Journal of Second Military Medical University, 21(10), 2000, 987.
Arends, et al., “A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma”,British Journal of Cancer, 92(3):445-448 (2005).
Corrie, et al., “Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients”,British Journal of Cancer, 87(7):716-719 (2002).
Gridelli, et al., “Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial”,Journal of the National Cancer Institute, 95(5):362-372 (2003).
Hill, et al., “Anti-Vascular Approaches to Solid Tumour Therapy: Evaluation of Vinblastine and Flavone Acetic Acid”,Int. J. Cancer, 63:119-123 (1995).
Jordan, et al., “Comparison of the Effects of Vinblastine, Vincristine, Vindesine, and Vinepidine on Microtubule Dynamics and Cell Proliferation in Vitro”,Cancer Research, 45:2741-2747 (1985).
Larsen, et al., “From DNA damage to G2 arrest : the many roles of topoisomerase II”,Progress in Cell Cycle Research, 5:295-300 (2003).
Onn, et al., “Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib”,British Journal of Cancer, 91(Suppl. 2):S11-S17 (2004).
Peters, et al., “Basis for effective combination cancer chemotherapy with antimetabolites”,Pharmacology&Therapeutics, 87:227-253 (2000).
PTCL Safety Glossary: Structure-Activity Relationship, ptcl.chem.ox.ac.uk/MSDS/glossary/structure—activity—relationship.html, Jun. 27, 2003, 1 page.
Strauss, et al., “A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma”,British Journal of Cancer, 89(10):1901-1905 (2003).
Wilson, et al. “Combination of the Antivascular Agent DMXAA with Radiation and Chemotherapy”,I. J. Radiation Oncology, 46(3):706, Feb. 2000.
U.S. Appl. No. 10/946,833 (now U.S. Patent No. 7,462,642)—Restriction R
Siim Bronwyn G.
Wilson William R.
Cancer Research Technology Limited
Marschel Ardin
Nelson Mullins Riley & Scarborough LLP
Rao Savitha
Trinque Brian C.
LandOfFree
Anti-cancer combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cancer combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer combinations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2691710